n-methyl-3,4-methylenedioxyamphetamine has been researched along with Stress Disorders, Post-Traumatic in 85 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Stress Disorders, Post-Traumatic: A class of traumatic stress disorders with symptoms that last more than one month.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The classical psychedelic drugs LSD and psilocybin and the entactogen MDMA are showing promise as tools to assist psychotherapy for a wide range of mental disorders, with multiple pilot studies demonstrating their safety and efficacy." | 4.98 | The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. ( Sessa, B, 2018) |
| "Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and Sheehan Disability Scale (SDS) functional impairment score (key secondary endpoint) were assessed by blinded independent assessors." | 3.30 | MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. ( Balliett, B; Bogenschutz, M; de Boer, A; Doblin, R; Gelfand, Y; Hamilton, S; Harrison, C; Kleiman, S; Mitchell, JM; Mithoefer, M; Nicholas, CR; Ot'alora G, M; Paleos, C; Parker-Guilbert, K; Quevedo, S; Shannon, S; Tzarfaty, K; van der Kolk, B; Yazar-Klosinski, B, 2023) |
| "MDMA-AT for ED-PTSD appears promising and requires further study." | 3.11 | MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. ( Brewerton, TD; Doblin, R; Emerson, A; Lafrance, A; Mithoefer, M; Pamplin, C; Wang, JB; Yazar-Klosinki, B, 2022) |
| "MDMA-AT for severe PTSD may also lead to subclinical improvements in alcohol use." | 3.11 | The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. ( Brown, RT; Coker, A; Doblin, R; Emerson, A; Klaire, SS; Mitchell, JM; Nicholas, CR; Wang, JB; Yazar-Klosinski, B, 2022) |
| "Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective." | 3.01 | MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. ( Amar, S; Amiaz, R; Bogenschutz, M; Brown, R; Carlin, S; Coker, A; de Boer, A; Doblin, R; Emerson, A; Garas, W; Gelfand, Y; Gorman, I; Hamilton, S; Hapke, E; Harrison, C; Klaire, SS; Kleiman, S; Lilienstein, A; Marta, C; Matthews, R; Mitchell, JM; Mithoefer, A; Mithoefer, M; Nicholas, C; Ot'alora G, M; Paleos, C; Parker-Guilbert, K; Poulter, B; Quevedo, S; Shannon, S; Tzarfaty, K; van der Kolk, B; Wallach, Y; Wang, JB; Wells, G; Woolley, JD; Worthy, R; Yazar-Klosinski, B, 2021) |
| "Symptoms of PTSD were measured using the CAPS-IV." | 3.01 | Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder. ( Feduccia, AA; Hamilton, S; Jerome, L; Mithoefer, MC; Ponte, L; Vermetten, E; Yazar-Klosinski, BB, 2021) |
| "MDMA-assisted psychotherapy for PTSD resulted in PTG and clinical symptom reductions of large-magnitude effect sizes." | 2.94 | Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder. ( Belser, AB; Emerson, A; Feduccia, AA; Gorman, I; Hamilton, S; Hennigan, C; Jerome, L; Shechet, B; Yazar-Klosinski, B, 2020) |
| "To examine long-term change in PTSD symptoms and additional benefits/harms after 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treatment of PTSD." | 2.94 | Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. ( Doblin, R; Emerson, A; Feduccia, AA; Hamilton, S; Jerome, L; Mithoefer, MC; Wang, JB; Yazar-Klosinski, B, 2020) |
| "Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments." | 2.87 | 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. ( Doblin, R; Emerson, A; Feduccia, AA; Hamilton, S; Holland, J; Jerome, L; Mithoefer, AT; Mithoefer, MC; Wagner, M; Wymer, J; Yazar-Klosinski, B, 2018) |
| "Change in the Clinician-Administered PTSD Scale total scores one month after two sessions of MDMA served as the primary outcome." | 2.87 | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. ( Doblin, R; Emerson, A; Feduccia, AA; Giron, SG; Grigsby, J; Hamilton, S; Jerome, L; Mithoefer, MC; Ot'alora G, M; Poulter, B; Van Derveer, JW; Yazar-Klosinski, B, 2018) |
| "The Clinician-Administered PTSD Scale (CAPS) Global Scores and NEO PI-R Personality Inventory (NEO) Openness and Neuroticism Scales served as outcome measures." | 2.84 | Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. ( Doblin, R; Jerome, L; MacAulay, RK; Mithoefer, AT; Mithoefer, MC; Wagner, MT; Yazar-Klosinski, B, 2017) |
| " The dosing of MDMA is used to allow the therapist to probe the underlying trauma without causing emotional distress." | 2.82 | MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis. ( Hernandez, AV; Sicignano, DJ; Smith, KW; White, CM, 2022) |
| ", selective serotonin reuptake inhibitors), so it will be important to understand drug-drug interactions between MDMA or psilocybin and psychiatric medications." | 2.82 | Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. ( Malcolm, B; Sarparast, A; Stauffer, CS; Thomas, K, 2022) |
| "Post-traumatic stress disorder (PTSD), characterized by abnormally persistent and distressing memories, is a chronic debilitating condition in need of new treatment options." | 2.82 | Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. ( Benedek, DM; Canales, JJ; Eri, R; Johnson, LR; Marathe, PA; Raut, SB; Ravindran, M; Ursano, RJ; van Eijk, L, 2022) |
| "Post-traumatic stress disorder (PTSD) is a debilitating mental illness with limited treatment options and a high treatment dropout rate." | 2.82 | Review of potential psychedelic treatments for PTSD. ( Henner, RL; Hill, KP; Keshavan, MS, 2022) |
| "Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event." | 2.82 | Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review. ( Gorczyca, P; Piegza, M; Pudlo, R; Szafoni, S; Więckiewicz, G, 2022) |
| " There were no drug-related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases." | 2.76 | The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. ( Doblin, R; Jerome, L; Mithoefer, AT; Mithoefer, MC; Wagner, MT, 2011) |
| "Some evidence suggests that Major Depressive Disorder (MDD) is the most common psychiatric condition that arises following trauma." | 2.72 | Psilocybin and MDMA for the treatment of trauma-related psychopathology. ( Bird, CIV; Modlin, NL; Rucker, JJH, 2021) |
| "Post-traumatic stress disorder (PTSD) has become one of the most common psychiatric diagnosis in the United States specifically within the veteran population." | 2.72 | MDMA to Treat PTSD in Adults. ( Abd-Elsayed, A; Cornett, EM; Green, J; Kaye, AD; Kaye, AM; Latimer, D; Sayers, K; Stocker, MD; Urits, I; Varrassi, G; Viswanath, O, 2021) |
| "Posttraumatic stress disorder (PTSD) is a common psychiatric condition that can develop following a traumatic experience." | 2.66 | Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis. ( Bahji, A; Forsyth, A; Groll, D; Hawken, ER, 2020) |
| "The rationale for the use of MDMA in PTSD and SUD is being extended to a broader beneficial "psychedelic effect," which is supporting further clinical investigations, in spite of the lack of mechanistic hypothesis." | 2.58 | Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. ( Chiamulera, C; Fattore, L; Fumagalli, G; Piva, A; Zanda, MT, 2018) |
| "There is a range of therapies to treat Post Traumatic Stress Disorder (PTSD) but treatment resistance remains high, with many sufferers experiencing the chronic condition." | 2.55 | MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics". ( Sessa, B, 2017) |
| "The most widely accepted treatment for PTSD is prolonged exposure (PE) therapy, but for many patients it is intolerable or ineffective." | 2.53 | Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. ( Amoroso, T; Workman, M, 2016) |
| "Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States." | 1.72 | Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. ( Kahn, JG; Marseille, E; Mitchell, JM, 2022) |
| "In this study, we aimed to test whether substance use in this population is related to an attempt to self-medicate PTSD-related symptoms." | 1.72 | Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders. ( Basedow, LA; Golub, Y; Kuitunen-Paul, S; Roessner, V; Wiedmann, MF, 2022) |
| "Adolescent patients with a substance use disorder (SUD) often fulfil the criteria for a co-occurring post-traumatic stress disorder (PTSD)." | 1.62 | Self-reported PTSD is associated with increased use of MDMA in adolescents with substance use disorders. ( Basedow, LA; Golub, Y; Kuitunen-Paul, S; Roessner, V; Wiedmann, MF, 2021) |
| "PTSD is a common comorbidity associated with EDs, and patients with EDs and PTSD (ED-PTSD) are reported to have higher severities of illness, greater comorbidities, higher treatment dropouts, and poorer outcomes." | 1.62 | The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD. ( Brewerton, TD; Lafrance, A; Mithoefer, MC, 2021) |
| "Between-group comparisons were made for PTSD and depression symptom severity at the baseline and the primary endpoint, and for peak vital signs across two MDMA sessions." | 1.62 | Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. ( Feduccia, AA; Holland, J; Jerome, L; Mithoefer, MC, 2021) |
| "Chronic posttraumatic stress disorder (PTSD) is a disabling condition that generates considerable morbidity, mortality, and both medical and indirect social costs." | 1.56 | The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. ( Doblin, R; Kahn, JG; Marseille, E; Yazar-Klosinski, B, 2020) |
| "Despite its efficacy in PTSD and anxiety, MDMA did not reduce either the subjective or objective responses to stress in this controlled study." | 1.46 | MDMA does not alter responses to the Trier Social Stress Test in humans. ( Bershad, AK; de Wit, H; Miller, MA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.18) | 18.2507 |
| 2000's | 9 (10.59) | 29.6817 |
| 2010's | 30 (35.29) | 24.3611 |
| 2020's | 45 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, IV | 2 |
| Barber, L | 1 |
| Dubnicka, TP | 1 |
| Hurtado, SB | 1 |
| Tincher, SA | 1 |
| Stankowski, LF | 1 |
| Yazar-Klosinski, B | 13 |
| Krystal, JH | 1 |
| Kelmendi, B | 1 |
| Petrakis, IL | 1 |
| Basedow, LA | 2 |
| Kuitunen-Paul, S | 2 |
| Wiedmann, MF | 2 |
| Roessner, V | 2 |
| Golub, Y | 2 |
| Halvorsen, JØ | 1 |
| Naudet, F | 1 |
| Cristea, IA | 1 |
| Smith, KW | 1 |
| Sicignano, DJ | 1 |
| Hernandez, AV | 1 |
| White, CM | 1 |
| Maples-Keller, JL | 2 |
| Norrholm, SD | 2 |
| Burton, M | 1 |
| Reiff, C | 1 |
| Coghlan, C | 1 |
| Jovanovic, T | 2 |
| Yasinski, C | 1 |
| Jarboe, K | 1 |
| Rakofsky, J | 1 |
| Rauch, S | 1 |
| Dunlop, BW | 2 |
| Rothbaum, BO | 4 |
| Marseille, E | 3 |
| Mitchell, JM | 4 |
| Kahn, JG | 3 |
| Avanceña, ALV | 1 |
| Sarparast, A | 1 |
| Thomas, K | 2 |
| Malcolm, B | 1 |
| Stauffer, CS | 1 |
| Brewerton, TD | 3 |
| Wang, JB | 5 |
| Lafrance, A | 2 |
| Pamplin, C | 1 |
| Mithoefer, M | 3 |
| Yazar-Klosinki, B | 1 |
| Emerson, A | 9 |
| Doblin, R | 14 |
| Nicholas, CR | 2 |
| Coker, A | 2 |
| Klaire, SS | 2 |
| Brown, RT | 1 |
| Raut, SB | 1 |
| Marathe, PA | 1 |
| van Eijk, L | 1 |
| Eri, R | 1 |
| Ravindran, M | 1 |
| Benedek, DM | 1 |
| Ursano, RJ | 1 |
| Canales, JJ | 1 |
| Johnson, LR | 1 |
| Arluk, S | 1 |
| Matar, MA | 1 |
| Carmi, L | 1 |
| Arbel, O | 1 |
| Zohar, J | 1 |
| Todder, D | 1 |
| Cohen, H | 1 |
| Henner, RL | 1 |
| Keshavan, MS | 1 |
| Hill, KP | 1 |
| Ching, TH | 1 |
| Williams, MT | 1 |
| Jerome, L | 11 |
| Kyarunts, M | 1 |
| Mansukhani, MP | 1 |
| Loukianova, LL | 1 |
| Kolla, BP | 1 |
| Barber, GS | 1 |
| Aaronson, ST | 1 |
| Bedi, G | 1 |
| Cotton, SM | 1 |
| Guerin, AA | 1 |
| Jackson, HJ | 1 |
| Madero, S | 1 |
| Alvarez, OD | 1 |
| Szafoni, S | 1 |
| Więckiewicz, G | 1 |
| Pudlo, R | 1 |
| Gorczyca, P | 1 |
| Piegza, M | 1 |
| Haridy, R | 1 |
| Nogrady, B | 1 |
| Ot'alora G, M | 3 |
| van der Kolk, B | 2 |
| Shannon, S | 2 |
| Bogenschutz, M | 2 |
| Gelfand, Y | 2 |
| Paleos, C | 2 |
| Quevedo, S | 2 |
| Balliett, B | 1 |
| Hamilton, S | 8 |
| Kleiman, S | 2 |
| Parker-Guilbert, K | 2 |
| Tzarfaty, K | 2 |
| Harrison, C | 2 |
| de Boer, A | 2 |
| Mullard, A | 1 |
| Holka-Pokorska, J | 1 |
| Flameling, LJ | 1 |
| Aday, JS | 1 |
| van Elk, M | 1 |
| Nafees, T | 1 |
| Wase, HA | 1 |
| Amir Malik, MF | 1 |
| Bahji, A | 1 |
| Forsyth, A | 1 |
| Groll, D | 1 |
| Hawken, ER | 1 |
| Vermetten, E | 2 |
| Yehuda, R | 1 |
| Gorman, I | 2 |
| Belser, AB | 1 |
| Hennigan, C | 1 |
| Shechet, B | 1 |
| Feduccia, AA | 9 |
| Mithoefer, MC | 13 |
| Oeri, HE | 1 |
| Holland, J | 3 |
| Illingworth, BJ | 1 |
| Lewis, DJ | 1 |
| Lambarth, AT | 1 |
| Stocking, K | 1 |
| Duffy, JM | 1 |
| Jelen, LA | 1 |
| Rucker, JJ | 1 |
| Tullis, P | 1 |
| Makunts, T | 1 |
| Abagyan, R | 1 |
| Schmid, Y | 1 |
| Gasser, P | 1 |
| Oehen, P | 3 |
| Liechti, ME | 1 |
| Lilienstein, A | 1 |
| Garas, W | 1 |
| Nicholas, C | 1 |
| Carlin, S | 1 |
| Poulter, B | 2 |
| Mithoefer, A | 2 |
| Wells, G | 1 |
| Amiaz, R | 1 |
| Worthy, R | 1 |
| Woolley, JD | 1 |
| Marta, C | 1 |
| Hapke, E | 1 |
| Amar, S | 1 |
| Wallach, Y | 1 |
| Brown, R | 1 |
| Matthews, R | 1 |
| Ponte, L | 1 |
| Yazar-Klosinski, BB | 2 |
| Bird, CIV | 1 |
| Modlin, NL | 1 |
| Rucker, JJH | 1 |
| Latimer, D | 1 |
| Stocker, MD | 1 |
| Sayers, K | 1 |
| Green, J | 1 |
| Kaye, AM | 1 |
| Abd-Elsayed, A | 1 |
| Cornett, EM | 1 |
| Kaye, AD | 1 |
| Varrassi, G | 1 |
| Viswanath, O | 1 |
| Urits, I | 1 |
| Bershad, AK | 1 |
| Miller, MA | 1 |
| de Wit, H | 2 |
| Sessa, B | 5 |
| Wagner, MT | 3 |
| Mithoefer, AT | 4 |
| MacAulay, RK | 1 |
| Young, MB | 1 |
| Khoury, LM | 1 |
| Rauch, SAM | 1 |
| Reiff, CM | 1 |
| Howell, LL | 1 |
| Fattore, L | 1 |
| Piva, A | 1 |
| Zanda, MT | 1 |
| Fumagalli, G | 1 |
| Chiamulera, C | 1 |
| Curran, HV | 1 |
| Nutt, D | 2 |
| Begola, MJ | 1 |
| Dowben, JS | 1 |
| Wagner, M | 2 |
| Wymer, J | 1 |
| Cipriani, A | 1 |
| Cowen, PJ | 1 |
| Gaddis, A | 1 |
| Lake, S | 1 |
| Tupper, K | 1 |
| Nosova, E | 1 |
| Blommaert, K | 1 |
| Wood, E | 1 |
| DeBeck, K | 1 |
| Schenk, S | 1 |
| Newcombe, D | 1 |
| Grigsby, J | 1 |
| Van Derveer, JW | 1 |
| Giron, SG | 1 |
| Walsh, Z | 1 |
| Chabrol, H | 1 |
| Kupferschmidt, K | 1 |
| Pathania, R | 1 |
| Corey, VR | 1 |
| Pisano, VD | 1 |
| Halpern, JH | 1 |
| Amoroso, T | 1 |
| Workman, M | 1 |
| Bouso, JC | 1 |
| Farré, M | 1 |
| Alcázar, MA | 1 |
| Gómez-Jarabo, G | 2 |
| Johansen, PØ | 1 |
| Krebs, TS | 1 |
| Cukor, J | 1 |
| Spitalnick, J | 1 |
| Difede, J | 1 |
| Rizzo, A | 1 |
| Traber, R | 1 |
| Widmer, V | 1 |
| Schnyder, U | 1 |
| Martin, SF | 1 |
| Michel, Y | 1 |
| Bouso Saiz, JC | 2 |
| Check, E | 1 |
| Morton, J | 1 |
| Caudevilla Gálligo, F | 1 |
| Falck, RS | 1 |
| Carlson, RG | 1 |
| Wang, J | 1 |
| Siegal, HA | 1 |
| Morris, K | 1 |
| Jansen, KL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of 3,4-methylenedioxymethamphetamine (MDMA) on Startle Response[NCT03181763] | Phase 1 | 34 participants (Actual) | Interventional | 2017-03-14 | Completed | ||
| A Randomized, Double-Blind, Dose Response Phase 2 Pilot Study of Manualized MDMA-Assisted Psychotherapy in Subjects With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)[NCT01793610] | Phase 2 | 29 participants (Actual) | Interventional | 2013-05-13 | Completed | ||
| A Randomized, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-assisted Psychotherapy in People With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)[NCT01689740] | Phase 2 | 10 participants (Actual) | Interventional | 2013-01-17 | Completed | ||
| Randomized, Triple-Blind, Phase 2 Pilot Study Comparing 3 Different Doses of MDMA in Conjunction With Manualized Therapy in 24 Veterans, Firefighters and Police Officers With Chronic Posttraumatic Stress Disorder (PTSD)[NCT01211405] | Phase 2 | 26 participants (Actual) | Interventional | 2010-11-10 | Completed | ||
| Phase II Clinical Trial Testing the Safety and Efficacy of 3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Chronic Posttraumatic Stress Disorder[NCT00090064] | Phase 2 | 23 participants (Actual) | Interventional | 2004-03-12 | Completed | ||
| EMPOWER Study: Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids: Observational Study With First Responders and Military Personnel Examining Previous Use Experience and Interest in Participating in Future Research S[NCT04965740] | 102 participants (Actual) | Observational | 2021-06-04 | Completed | |||
| A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada[NCT01958593] | Phase 2 | 6 participants (Actual) | Interventional | 2014-10-14 | Terminated (stopped due to This pilot study was terminated early by sponsor due to insufficient rate of accrual.) | ||
| Phase II Pilot Randomized Double-Blind Placebo-Controlled Study of 3,4-methylenedioxymethamphetamine (MDMA)Assisted Psychotherapy in Posttraumatic Stress Disorder (PTSD)- Switzerland[NCT00353938] | Phase 2 | 14 participants (Actual) | Interventional | 2006-09-13 | Completed | ||
| MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II Study[NCT05783817] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder[NCT03537014] | Phase 3 | 100 participants (Actual) | Interventional | 2018-11-21 | Completed | ||
| A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD[NCT05790239] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| MDMA-Assisted Therapy 6 to 12 Months After Childbirth for People With Co-occurring Opioid Use and Post Traumatic Stress Disorders[NCT05219175] | Phase 2 | 15 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
| Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial[NCT05554094] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| The Effects of MDMA on Prefrontal and Amygdala Activation in Posttraumatic Stress Disorder[NCT03752918] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms. (NCT01793610)
Timeframe: Baseline Enrollment
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose MDMA (40 mg) and Psychotherapy | 23.8 |
| Active Dose 2 MDMA (100 mg) and Psychotherapy | 28.2 |
| Active Dose 1 MDMA (125 mg) and Psychotherapy | 29.3 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms. (NCT01793610)
Timeframe: One month after 2nd experimental session (approximately 3 months post enrollment)
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose MDMA (40 mg) and Psychotherapy | 12.3 |
| Active Dose 2 MDMA (100 mg) and Psychotherapy | 18.3 |
| Active Dose 1 MDMA (125 mg) and Psychotherapy | 17.3 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms. (NCT01793610)
Timeframe: Baseline Enrollment to 1-Month Post 2nd Experimental Session
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose (40 mg) MDMA and Psychotherapy | -11.5 |
| Active Dose 2 (100 mg) MDMA and Psychotherapy | -9.9 |
| Active Dose 1 (125 mg) MDMA and Psychotherapy | -11.0 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01793610)
Timeframe: Baseline Enrollment to 1-Month Post 2nd Experimental Session
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose (40 mg) MDMA and Psychotherapy | -11.5 |
| Active Dose 2 (100 mg) MDMA and Psychotherapy | -24.4 |
| Active Dose 1 (125 mg) MDMA and Psychotherapy | -26.3 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality. (NCT01793610)
Timeframe: Baseline Enrollment to 1-Month Post 2nd Experimental Session
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose (40 mg) MDMA and Psychotherapy | -0.83 |
| Active Dose 2 (100 mg) MDMA and Psychotherapy | -3.56 |
| Active Dose 1 (125 mg) MDMA and Psychotherapy | -1.92 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01793610)
Timeframe: Baseline Enrollment
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose MDMA (40 mg) and Psychotherapy | 84.8 |
| Active Dose 2 MDMA (100 mg) and Psychotherapy | 94.4 |
| Active Dose 1 MDMA (125 mg) and Psychotherapy | 93.5 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01793610)
Timeframe: One month after 2nd experimental session (approximately 3 months post enrollment)
| Intervention | score on a scale (Mean) |
|---|---|
| Comparator-dose MDMA (40 mg) and Psychotherapy | 73.3 |
| Active Dose 2 MDMA (100 mg) and Psychotherapy | 70.0 |
| Active Dose 1 MDMA (125 mg) and Psychotherapy | 64.3 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63. (NCT01689740)
Timeframe: End of Stage 1 to End of Stage 2
| Intervention | score on a scale (Mean) |
|---|---|
| Active Placebo Dose MDMA (25 mg)/ Stage 2 Crossover | -6.0 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63. (NCT01689740)
Timeframe: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -17.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | 0.33 |
| Full Dose MDMA (125 mg) and Psychotherapy | -17.0 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63. (NCT01689740)
Timeframe: Baseline to 12 month post-final experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -17.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -3.5 |
| Full Dose MDMA (125 mg) and Psychotherapy | -18.4 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01689740)
Timeframe: Baseline to 1-Month Post Experimental Session 2 (End of Stage 1)
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -42.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -9.0 |
| Full Dose MDMA (125 mg) and Psychotherapy | -34.6 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01689740)
Timeframe: Baseline to 12 months post-final experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -39.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -34.5 |
| Full Dose MDMA (125 mg) and Psychotherapy | -48.8 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01689740)
Timeframe: End of Stage 1 to End of Stage 2
| Intervention | score on a scale (Mean) |
|---|---|
| Active Placebo Dose MDMA (25 mg)/ Stage 2 Crossover | -10.0 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning. (NCT01689740)
Timeframe: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | 15.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -2.33 |
| Full Dose MDMA (125 mg) and Psychotherapy | 18.2 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning. (NCT01689740)
Timeframe: Baseline to 12 months post-final experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | 5 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -2.0 |
| Full Dose MDMA (125 mg) and Psychotherapy | 26.6 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning. (NCT01689740)
Timeframe: End of Stage 1 to End of Stage 2
| Intervention | score on a scale (Mean) |
|---|---|
| Active Placebo Dose MDMA (25 mg)/ Stage 2 Crossover | 11.5 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality. (NCT01689740)
Timeframe: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -7.5 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | 1.0 |
| Full Dose MDMA (125 mg) and Psychotherapy | -1.8 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality. (NCT01689740)
Timeframe: Baseline to 12 months post-final experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -3.5 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -2.0 |
| Full Dose MDMA (125 mg) and Psychotherapy | -2.2 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality. (NCT01689740)
Timeframe: End of Stage 1 to End of Stage 2
| Intervention | score on a scale (Mean) |
|---|---|
| Active Placebo Dose MDMA (25 mg)/ Stage 2 Crossover | -3.5 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms. (NCT01689740)
Timeframe: Baseline to 1-Month Post 2nd Experimental Session (End of Stage 1)
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -19.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | 1.33 |
| Full Dose MDMA (125 mg) and Psychotherapy | -17.4 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms. (NCT01689740)
Timeframe: Baseline to 12 months post-final experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Lead in: 125 mg MDMA (Open Label) and Psychotherapy | -23.0 |
| Active Placebo Dose MDMA (25 mg) and Psychotherapy | -10 |
| Full Dose MDMA (125 mg) and Psychotherapy | -20.4 |
The Posttraumatic Stress Diagnostic Scale (PDS) is a 49-item self-report instrument designed to aid in the diagnosis of PTSD. Responses to 17 symptom items are made on a 4 point scale ranging from 0 (not at all) to 3 (five or more times per week). The symptom items are summed to calculate the symptom severity score which ranges from 0 to 51, with higher scores indicating more severe PTSD symptoms. (NCT01689740)
Timeframe: End of Stage 1 to End of Stage 2
| Intervention | score on a scale (Mean) |
|---|---|
| Active Placebo Dose MDMA (25 mg)/ Stage 2 Crossover | -10.0 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01211405)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | 87.4 |
| Medium Dose MDMA (75 mg) | 82.4 |
| Full Dose MDMA (125 mg) | 89.7 |
Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The BDI-II is scored by summing the ratings for the 21 items. Each item is rated on a 4-point scale ranging from 0 to 3. The maximum total score is 63. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | -4.6 |
| Medium Dose MDMA (75 mg) | -15.4 |
| Full Dose MDMA (125 mg) | -24.6 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | -11.4 |
| Medium Dose MDMA (75 mg) | -58.3 |
| Full Dose MDMA (125 mg) | -44.3 |
"The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. Respondents indicate how often the specific experience happens to them, from never (0% of the time) to always (100%). The scale is scored by treating percentages as single digits and summing to produce a total score, ranging from 0 to 100. The higher the score, the more dissociative symptoms." (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | 1.8 |
| Medium Dose MDMA (75 mg) | -8.6 |
| Full Dose MDMA (125 mg) | -8.8 |
The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | 1.1 |
| Medium Dose MDMA (75 mg) | 19.4 |
| Full Dose MDMA (125 mg) | 18.4 |
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | 1.8 |
| Medium Dose MDMA (75 mg) | -6.4 |
| Full Dose MDMA (125 mg) | -4.8 |
The Posttraumatic Growth Inventory (PTGI) is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales; relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. Questions are answered on a scale from 0 (I did not experience this change) to 5 (I experienced this change to a great degree). Items are added to calculate the total PTGI score which ranges from 0 to 105, with higher scores indicative of greater growth. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | -11.6 |
| Medium Dose MDMA (75 mg) | 36.1 |
| Full Dose MDMA (125 mg) | 33.7 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01211405)
Timeframe: One month after second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| Low Dose MDMA (30 mg) | 76.0 |
| Medium Dose MDMA (75 mg) | 24.1 |
| Full Dose MDMA (125 mg) | 45.3 |
The NEO-PI-R is a 240-item self-report assessment that defines personality structure according to a five-factor model. Items related to neuroticism, extraversion, openness, agreeableness, and conscientiousness are rated on a five-point scale from strongly disagree to strongly agree. T-scores range from 20 to 80 with a mean score of 50. Higher scores in each domain indicating stronger facets of those personality factors. The NEO-PI-R is a measure of personality traits, not psychopathology symptoms. (NCT01211405)
Timeframe: Baseline to one month after second experimental session
| Intervention | T-score (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline Neuroticism | One month after 2nd Experimental Session Neuroticism | Change in Neuroticism | Baseline Extroversion | One month after 2nd Experimental Session Extroversion | Change in Extroversion | Baseline Openness | One Month after 2nd Experimental Session Openness | Change in Openness | Baseline Agreeableness | One Month after 2nd Experimental Session | Change in Agreeableness | Baseline Conscientiousness | One Month after 2nd Experimental Session Conscientiousness | Change in Conscientiousness | |
| Full Dose MDMA (125 mg) | 75.1 | 58.6 | -16.5 | 34.2 | 42.2 | 8.0 | 57.4 | 59.4 | 2.0 | 39.8 | 45.7 | 5.9 | 41.3 | 47.8 | 6.5 |
| Low Dose MDMA (30 mg) | 62.0 | 60.2 | -4.6 | 33.1 | 36.0 | 2.2 | 48.9 | 49.2 | -0.6 | 44.7 | 40.6 | -1.2 | 41.3 | 39.8 | -3.2 |
| Medium Dose MDMA (75 mg) | 65.3 | 53.6 | -12.0 | 37.4 | 46.4 | 10.0 | 55.6 | 66.0 | 15.6 | 33.1 | 33.4 | 5.4 | 53.6 | 56.4 | 2.4 |
The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT00090064)
Timeframe: Baseline to 2 months post second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -55.2 |
| Placebo With Therapy | -20.5 |
"The Impact of Events Scale Revised (IES-R) is a 22-item self-report measure (for DSM-IV) designed to measure the extent to which a given stressful life event produces subjective distress. Each item corresponds directly to 14 of the 17 DSM-IV symptoms of PTSD and is rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely) for the extent to which the item was true for the participant during the past seven days. The IES-R yields a total score ranging from 0 to 88 with higher scores indicated greater distress." (NCT00090064)
Timeframe: Baseline to 2 months post second experimental session
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -29.7 |
| Placebo With Therapy | -12.9 |
Clinician-administered and scored assessment of PTSD symptoms via structured interview, including global symptom severity, dichotomous diagnostic score and subscale scores. The Clinician-Administered PTSD Scale for DSM-4 (CAPS-4) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-4. It contains symptom subscales, a CAPS-4 total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT01958593)
Timeframe: Baseline to Primary Endpoint (Primary Endpoint was approximately 18 weeks after Baseline and 1 month after the 2nd experimental session)
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo With Therapy | -21.5 |
| MDMA-assisted Therapy | -17.3 |
The CAPS-IV is a structured clinical interview designed to assess the symptoms and severity of PTSD. The CAPS-IV provides a means to evaluate the frequency and intensity dimensions of each symptom, the impact of symptoms on the patient's social and occupational functioning, the overall severity of the symptom complex, global improvement since baseline, and the validity of the ratings obtained. Total severity scores range from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT00353938)
Timeframe: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
| Intervention | score on a scale (Mean) |
|---|---|
| Full Dose MDMA-assisted Therapy (125 mg) | -15.6 |
| Active Placebo MDMA-assisted Therapy (25 mg) | -3.2 |
"The Posstraumatic Stress Diagnostic Scale (PSD) is a 49-item self-report instrument to aid in the diagnosis of PTSD. Questions are asked about symptoms experienced and participants respond on a scale from 0 (not at all or only one time) to 3 (5 or more times a week/almost always). Items are summed to create a total score that ranges from 0 to 51, with higher scores indicating more PTSD symptoms." (NCT00353938)
Timeframe: Less than 4 weeks before first experimental session (Baseline) to 3 weeks post 3rd experimental session (Primary Endpoint)
| Intervention | score on a scale (Mean) |
|---|---|
| Full Dose MDMA-assisted Therapy (125 mg) | -8.6 |
| Active Placebo MDMA-assisted Therapy (25 mg) | 7.3 |
The Clinician-Administered PTSD Scale for DSM-V (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms. (NCT03537014)
Timeframe: Baseline to 18 weeks post enrollment confirmation
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -24.4 |
| Placebo With Therapy | -13.9 |
The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment that was adapted for the purposes of this study to limit missing item-level data as per the FDA requirements and included use of the three-item mean as the total score and imputation of work-related impairment. The SDS is a 3-item scale measuring the severity of disability in the domains of work, family life/home responsibilities and social/leisure activities, with each item scored on a ten-point Likert scale from 0 ('not at all impaired') to 10 ('very severely impaired'). The SDS total score was the mean of the 3 item responses. The SDS total score ranged from 0 to 10, with higher scores indicating greater functional impairment. (NCT03537014)
Timeframe: Baseline to 18 weeks post enrollment confirmation
| Intervention | score on a scale (Mean) |
|---|---|
| MDMA-assisted Therapy | -3.1 |
| Placebo With Therapy | -2.0 |
24 reviews available for n-methyl-3,4-methylenedioxyamphetamine and Stress Disorders, Post-Traumatic
| Article | Year |
|---|---|
MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis.
Topics: Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Dis | 2022 |
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.
Topics: Adult; Drug Interactions; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; | 2022 |
Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation.
Topics: Cannabinoids; Fear; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Po | 2022 |
Review of potential psychedelic treatments for PTSD.
Topics: Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychother | 2022 |
MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans | 2022 |
The Emerging Field of Psychedelic Psychotherapy.
Topics: Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Psychotherapy; Stress Dis | 2022 |
MDMA-assisted psychotherapy for post-traumatic stress disorder: The devil is in the detail.
Topics: Australia; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Diso | 2023 |
Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
Topics: Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Dis | 2022 |
Can research on entactogens contribute to a deeper understanding of human sexuality?
Topics: Emotions; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Sexuality; Stress Disorders | 2023 |
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality | 2020 |
Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.
Topics: Animals; Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; P | 2021 |
A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis.
Topics: Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychiatri | 2021 |
Psilocybin and MDMA for the treatment of trauma-related psychopathology.
Topics: Depressive Disorder, Major; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disor | 2021 |
MDMA to Treat PTSD in Adults.
Topics: Adult; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Disorder | 2021 |
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.
Topics: Adolescent; Child; Child Abuse; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychiatry; Serotoni | 2017 |
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.
Topics: Animals; Data Collection; Emotions; Forecasting; Hallucinogens; Humans; Mental Disorders; N-Methyl-3 | 2018 |
Progress and promise for the MDMA drug development program.
Topics: Affect; Animals; Brain; Clinical Trials, Phase II as Topic; Drug Development; Fear; Hallucinogens; H | 2018 |
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine.
Topics: Anesthetics, Dissociative; Animals; Appetitive Behavior; Cannabinoids; Emotions; Hallucinogens; Huma | 2018 |
MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?
Topics: Animals; Clinical Trials as Topic; Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamp | 2018 |
Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions.
Topics: Humans; N-Methyl-3,4-methylenedioxyamphetamine; Neurotransmitter Agents; Stress Disorders, Post-Trau | 2018 |
Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy.
Topics: Clinical Trials as Topic; Humans; Implosive Therapy; N-Methyl-3,4-methylenedioxyamphetamine; Psychot | 2016 |
MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics".
Topics: Animals; Clinical Trials as Topic; Humans; Memory; N-Methyl-3,4-methylenedioxyamphetamine; Stress Di | 2017 |
Emerging treatments for PTSD.
Topics: Cognitive Behavioral Therapy; Combat Disorders; Computer Simulation; Cycloserine; Humans; Implosive | 2009 |
Ecstasy: pharmacology and neurotoxicity.
Topics: Affect; Animals; Binding Sites; Brain; Fever; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamph | 2005 |
18 trials available for n-methyl-3,4-methylenedioxyamphetamine and Stress Disorders, Post-Traumatic
| Article | Year |
|---|---|
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.
Topics: Animals; Extinction, Psychological; Fear; Female; Humans; Male; N-Methyl-3,4-methylenedioxyamphetami | 2022 |
MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Feeding and Eating Disorders; Female; Humans; | 2022 |
The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD.
Topics: Adult; Alcoholism; Combined Modality Therapy; Ethanol; Humans; N-Methyl-3,4-methylenedioxyamphetamin | 2022 |
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.
Topics: Combined Modality Therapy; Double-Blind Method; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Stre | 2023 |
MDMA-assisted therapy for PTSD passes phase III trial.
Topics: Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Stress Dis | 2023 |
Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder.
Topics: Adult; Female; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Non-Randomized Con | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.
Topics: Adult; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2020 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Drug-Related Side Effects and Adverse Reactio | 2021 |
Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.
Topics: Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Sleep; Sle | 2021 |
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.
Topics: Adult; Combined Modality Therapy; Female; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyam | 2017 |
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Firefighters; Humans; N-Methyl-3,4-met | 2018 |
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Firefighters; Humans; N-Methyl-3,4-met | 2018 |
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Firefighters; Humans; N-Methyl-3,4-met | 2018 |
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Firefighters; Humans; N-Methyl-3,4-met | 2018 |
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.
Topics: Adult; Aged; Combined Modality Therapy; Cross-Over Studies; Dose-Response Relationship, Drug; Double | 2018 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Midd | 2019 |
Effects of 3,4-Methylenedioxymethamphetamine on Patient Utterances in a Psychotherapeutic Setting.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Humans; Male; N-Methyl-3,4-methylened | 2016 |
MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Me | 2008 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fear; Female; Humans; Male; Middle Aged; Music | 2011 |
A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD).
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Mal | 2013 |
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Topics: Adult; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; N-Methyl-3,4-methylenedioxyamphetamin | 2013 |
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Topics: Adult; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; N-Methyl-3,4-methylenedioxyamphetamin | 2013 |
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Topics: Adult; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; N-Methyl-3,4-methylenedioxyamphetamin | 2013 |
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.
Topics: Adult; Female; Follow-Up Studies; Humans; Illicit Drugs; Male; N-Methyl-3,4-methylenedioxyamphetamin | 2013 |
43 other studies available for n-methyl-3,4-methylenedioxyamphetamine and Stress Disorders, Post-Traumatic
| Article | Year |
|---|---|
Three regulatory compliant test systems show no signs of MDMA-related genotoxicity.
Topics: Animals; CHO Cells; Chromosome Aberrations; Cricetulus; Escherichia coli; Female; Male; Mutagenicity | 2021 |
Psychotherapy-supported MDMA treatment for PTSD.
Topics: Combined Modality Therapy; Humans; Medicine; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; | 2021 |
Self-reported PTSD is associated with increased use of MDMA in adolescents with substance use disorders.
Topics: Adolescent; Diagnosis, Dual (Psychiatry); Germany; Hallucinogens; Humans; N-Methyl-3,4-methylenediox | 2021 |
Challenges with benchmarking of MDMA-assisted psychotherapy.
Topics: Benchmarking; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Disorders, Post- | 2021 |
Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial.
Topics: Adaptation, Physiological; Adult; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female | 2022 |
The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study.
Topics: Cost-Benefit Analysis; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Quality-Adjust | 2022 |
MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats.
Topics: Animals; Anti-Anxiety Agents; Cues; Disease Models, Animal; Hypothalamo-Hypophyseal System; N-Methyl | 2022 |
The promise of 3,4-methylenedioxymethamphetamine (MDMA) in combination with prolonged exposure therapy for posttraumatic stress disorder.
Topics: Hallucinogens; Humans; Implosive Therapy; N-Methyl-3,4-methylenedioxyamphetamine; Stress Disorders, | 2023 |
Assessing the quality of publicly available videos on MDMA-assisted psychotherapy for PTSD.
Topics: Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Reproducibility of Results; Social Me | 2022 |
Coping motives mediate the relationship between PTSD and MDMA use in adolescents with substance use disorders.
Topics: Adaptation, Psychological; Adolescent; Female; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; | 2022 |
Premise, promise and challenges of MDMA assisted therapy for PTSD.
Topics: Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychother | 2023 |
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
Topics: Australia; Depression; Drug Approval; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; St | 2023 |
Australia's approval of MDMA and psilocybin for PTSD and depression is premature, say critics.
Topics: Australia; Depression; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, | 2023 |
Expectancy Effects Cannot Be Neglected in MDMA-Assisted Therapy Research.
Topics: Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Dis | 2023 |
News Brief: MDMA therapy for PTSD.
Topics: Humans; N-Methyl-3,4-methylenedioxyamphetamine; Stress Disorders, Post-Traumatic | 2023 |
Is the 3,4-Methylenedioxymethamphetamine assisted psychotherapy a novel approach to managing post-traumatic stress disorder?
Topics: Combined Modality Therapy; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Serotonin | 2019 |
MDMA-assisted psychotherapy for posttraumatic stress disorder: A promising novel approach to treatment.
Topics: Combined Modality Therapy; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psychother | 2020 |
The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD.
Topics: Adult; Chronic Disease; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Double-Blind Meth | 2020 |
The potential use of N-methyl-3,4-methylenedioxyamphetamine (MDMA) assisted psychotherapy in the treatment of eating disorders comorbid with PTSD.
Topics: Combined Modality Therapy; Feeding and Eating Disorders; Humans; N-Methyl-3,4-methylenedioxyamphetam | 2021 |
Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Topics: Adult; Antidepressive Agents; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Double- | 2021 |
How ecstasy and psilocybin are shaking up psychiatry.
Topics: Animals; Certification; Clinical Trials as Topic; Depression; Depressive Disorder, Treatment-Resista | 2021 |
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Cause of Death; Databases, Factual; | 2021 |
Acute subjective effects in LSD- and MDMA-assisted psychotherapy.
Topics: Adult; Combined Modality Therapy; Compassionate Use Trials; Consciousness Disorders; Depressive Diso | 2021 |
MDMA does not alter responses to the Trier Social Stress Test in humans.
Topics: Anxiety; Blood Pressure; Central Nervous System Stimulants; Exercise Test; Hallucinogens; Heart Rate | 2017 |
Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).
Topics: Animals; Dose-Response Relationship, Drug; Extinction, Psychological; Fear; Male; Memory; Mice; Mice | 2017 |
Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation.
Topics: Animals; Brain; Hallucinogens; Humans; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Str | 2018 |
The re-emergence of hallucinogenic research.
Topics: Hallucinogens; History, 20th Century; History, 21st Century; Humans; N-Methyl-3,4-methylenedioxyamph | 2018 |
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in service personnel.
Topics: Brief Psychiatric Rating Scale; Dose-Response Relationship, Drug; Humans; Military Personnel; N-Meth | 2018 |
Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs.
Topics: Adolescent; Canada; Cohort Studies; Female; Hallucinogens; Homeless Youth; Humans; Illicit Drugs; Ma | 2018 |
MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder.
Topics: Female; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Disorders, Post- | 2013 |
Reply to the letter to the editor by H Chabrol.
Topics: Female; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Psychotherapy; Stress Disorders, Post- | 2013 |
Can ecstasy treat the agony of PTSD?
Topics: Brain; Clinical Trials, Phase II as Topic; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Receptors | 2014 |
Making a medicine out of MDMA.
Topics: Humans; N-Methyl-3,4-methylenedioxyamphetamine; Stress Disorders, Post-Traumatic | 2015 |
Therapeutic potential of psychedelic agents.
Topics: Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetam | 2015 |
Turn on and tune in to evidence-based psychedelic research.
Topics: Anxiety Disorders; Biomedical Research; Chemotherapy, Adjuvant; Hallucinogens; Humans; Lysergic Acid | 2015 |
Potential Psychiatric Uses for MDMA.
Topics: Adrenergic Uptake Inhibitors; Clinical Trials, Phase II as Topic; Humans; N-Methyl-3,4-methylenediox | 2017 |
How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale.
Topics: Anxiety Disorders; Avoidance Learning; Brain; Empathy; Fear; Humans; N-Methyl-3,4-methylenedioxyamph | 2009 |
[Therapeutic investigation with MDMA (ecstasy)].
Topics: Adult; Clinical Trials as Topic; Combined Modality Therapy; Female; Hallucinogens; Humans; N-Methyl- | 2003 |
Psychedelic drugs: the ups and downs of ecstasy.
Topics: Agaricales; Animals; Anxiety; Brain; Cactaceae; Controlled Clinical Trials as Topic; Female; Halluci | 2004 |
[Ecstasy: is it innocuous?].
Topics: Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cognition | 2005 |
Psychiatric disorders and their correlates among young adult MDMA users in Ohio.
Topics: Adolescent; Adult; Analysis of Variance; Depressive Disorder; Female; Humans; Interviews as Topic; M | 2006 |
Research on psychedelics moves into the mainstream.
Topics: Cluster Headache; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Pilot Projects; Psy | 2008 |
Ecstasy (MDMA) dependence.
Topics: Adult; Hallucinogens; Humans; Male; N-Methyl-3,4-methylenedioxyamphetamine; Seizures; Self Medicatio | 1999 |